Here we observed that, on the one hand, the treatment with Ocoxin upregulated ESPL1 and downregulated PTTG1 in TNBC and PAAD, and on the other hand, ESPL1 was downregulated in PRAD and COAD, but PTTG1 was not altered. This evidence concerns the gene ESPL1 and prostate adenocarcinoma.